Medications for Alcohol Craving Management

First-Line Medications

The American College of Physicians recommends naltrexone 50 mg daily for reducing alcohol cravings and preventing relapse to heavy drinking, with a critical timing requirement of initiation 3-7 days after the last alcohol consumption and only after withdrawal symptoms have completely resolved 1
The American Medical Association suggests acamprosate 666 mg three times daily (1,998 mg/day total) as an equally effective alternative for maintaining abstinence, particularly for patients who prioritize complete abstinence over harm reduction, with a mechanism of modulating glutamatergic receptors and reducing withdrawal effects and craving 2, 3

The National Institute of Diabetes and Digestive and Kidney Diseases recommends baclofen as the only medication proven safe and effective for patients with alcoholic liver disease or cirrhosis, with a dosing protocol that increases abstinence rates and prevents relapse 2, 1, 3
The American Association for the Study of Liver Diseases suggests gabapentin 1800 mg/day (600 mg three times daily) as a second-line treatment, particularly effective in patients with liver disease, with a number needed to treat of 8 for abstinence and 5 for non-excessive drinking 3

The American College of Gastroenterology warns that naltrexone carries a risk of hepatotoxicity and is contraindicated in patients with alcoholic liver disease, acute hepatitis, or decompensated cirrhosis, with a recommendation to obtain baseline liver function tests and monitor every 3-6 months during treatment 1, 3
The National Kidney Foundation notes that acamprosate has no hepatotoxicity risk and is safe in liver disease, but is contraindicated in severe renal impairment (creatinine clearance ≤30 mL/min) and requires dose reduction for moderate renal impairment (30-50 mL/min) 3

The American Medical Association recommends assessing liver function and renal function before selecting medication, with a treatment algorithm that includes choosing naltrexone 50 mg daily or acamprosate 1,998 mg/day for patients without significant liver disease, and using baclofen or gabapentin for patients with alcoholic liver disease or cirrhosis 1, 2, 3